THE SENATE TWENTY-FIFTH LEGISLATURE, 2010 STATE OF HAWAII

S.B. NO. $^{2810}_{S.D.2}$

A BILL FOR AN ACT

RELATING TO PRESCRIPTION DRUGS.

.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1. Chapter 461, Hawaii Revised Statutes, is
2	amended by adding a new part to be appropriately designated and
3	to read as follows:
4	"PART . MEDICATION THERAPY MANAGEMENT
5	§461-A Definitions. As used in this part, unless the
6	context requires otherwise:
7	"Collaborative pharmacy practice" is that practice of
8	pharmacy whereby one or more pharmacists have jointly agreed, on
9	a voluntary basis, to work in conjunction with one or more
10	practitioners under protocol whereby the pharmacist may perform
11	certain patient care functions authorized by the practitioner or
12	practitioners under certain specified conditions or limitations.
13	"Collaborative pharmacy practice agreement" is a written
14	and signed agreement between one or more pharmacists and one or
15	more practitioners that provides for collaborative pharmacy
16	practice for the purpose of conducting medication therapy
17	management activities, as defined by law and the rules of the
18	board.
	SB2810 SD2 LRB 10-1886 doc



"Medication therapy" means the treatment of disease or 1 2 disorder through the use of prescription or non-prescription 3 medications. 4 "Protected health information" means any information 5 related to a person's health status or consumption of health 6 care services that is protected from public disclosure by 7 federal or state law. "Qualified patient" means an individual who has 8 prescription drug coverage through QUEST. 9 10 §461-B Capacity for medication therapy management 11 required. (a) Each pharmacy in the State that provides 12 pharmacy services to qualified patients shall maintain the capacity to offer medication therapy management services 13 14 pursuant to this part. 15 A pharmacy shall meet the requirements of subsection (b) 16 (a) if the pharmacy employs at least one registered pharmacist 17 who is party to a collaborative agreement allowing the 18 pharmacist to provide medication therapy management and that 19 pharmacist is present and available to provide medication management services on at least a half-time basis. 20 21 (C) A remote dispensing pharmacy operating pursuant to 22 section 461-10.5 shall meet the requirements of subsection (a)



if its responsible pharmacy meets the requirements of subsection 1 2 (a) and a qualified patient has access to medication therapy 3 management services through the video component required by 4 section 461-10.5(h)(5). 5 **§461-C** Notice of availability. Each qualified patient 6 shall be made aware of the availability of medication therapy 7 management services: Verbally, each time the qualified patient receives a 8 (1)prescription that is covered by QUEST from a pharmacy; 9 10 In writing via a notice that complies with (2) 11 requirements specified by the board pursuant to 12 section 461-G; and By posting of notice that complies with requirements 13 (3) 14 specified by the board pursuant to section 461-G. 15 §461-D Scope of service. (a) Medication therapy 16 management is a distinct service or group of services with the 17 goal of optimizing therapeutic outcomes for individual qualified patients and is independent of, but can occur in conjunction 18 19 with, the provision of a medication or a medical device. 20 Medication therapy management encompasses a broad range of 21 professional activities and responsibilities within the 22 registered pharmacist's scope of practice. These services may SB2810 SD2 LRB 10-1886.doc

1	include,	but are not limited to, the following, according to the
2	individua	l needs of the qualified patient:
3	(1)	Performing or obtaining necessary assessments of the
4		qualified patient's health status;
5	(2)	Formulating a medication treatment plan;
6	(3)	Selecting, initiating, modifying, or administering
7		medication therapy;
8	(4)	Monitoring and evaluating the qualified patient's
9		response to medication therapy, including assessment
10		of safety and effectiveness of individual medications;
11	(5)	Performing a comprehensive medication review to
12		identify, resolve, and prevent medication-related
13		problems including adverse events;
14	(6)	Documenting the care delivered and communicating
15		essential information to the qualified patient's other
16		care providers as authorized by the qualified patient;
17	(7)	Providing verbal education and training designed to
18		enhance the qualified patient's understanding and
19		appropriate use of medications;
20	(8)	Providing information, support services, and resources
21		designed to enhance the qualified patient's adherence
22		to therapeutic regimens; and

S.B. NO. 2810 S.D. 2

1	(9)	Coordinating and integrating medication therapy
2		management services within the broader health care
3		management services being provided to the qualified
4		patient.
5	(b)	Medication therapy management shall include a review
6	of the qua	alified patient's medical records and each prescription
7	drug that	the qualified patient regularly or currently takes to
8	identify:	
9	(1)	Known allergies;
10	(2)	Rational therapy contraindications;
11	(3)	Reasonable dose, duration of use, and route of
12		administration of medications, considering the
13		qualified patient's age, gender, and other patient
14		factors;
15	(4)	Reasonable directions for use of each medication that
16	· · · · · · · · · · · · · · · · · · ·	the qualified patient takes;
17	(5)	Potential or actual adverse drug reactions;
18	(6)	Drug-drug interactions;
19	(7)	Drug-food interactions;
20	(8)	Drug-disease contraindications;

Page 6

1	(9)	Duplications or redundancy among drugs or therapies
2		that are part of the qualified patient's medication
3		therapy;
4	(10)	Proper utilization of medication therapy, avoidance of
5		over- or under-utilization of medication therapy, and
6		optimum therapeutic outcomes; and
7	(11)	Abuse or misuse of medication therapy.
8	Upon	recognizing any of the above, a pharmacist shall take
9	appropriat	te steps to avoid or resolve the problem which may
10	include co	onsultation with the qualified patient's health care
11	providers	
12	(C)	At the time that a qualified patient who receives
13	medication	n therapy management services begins taking a new
14	prescript	ion medication for the first time, the pharmacist
15	providing	medication therapy management shall review the
16	qualified	patient's record and provide patient counseling
17	regarding	the therapeutic use of the new medication and the
18	interactio	on of the new drug with the qualified patient's
19	existing r	medication therapy. Counseling pursuant to this
20	subsection	n shall include:
21	(1)	The brand name, generic name, if applicable, and an
22		accurate description of the medication;
	ap0010 ap0	



S.B. NO. 2810 S.D. 2

1	(2)	The preścribed dosage form, dose, route of
2		administration, and duration of the medication
3		therapy;
4	(3)	The intended use of the medication and its expected
5		action;
6	(4)	Special directions and precautions for preparation,
7		administration, and use of the medication by the
8		qualified patient;
9	(5)	Common severe side effects, adverse effects,
10		interactions, and therapeutic contraindications that
11		may be encountered, means of avoiding any adverse
12		effects, and the action required if they occur;
13	(6)	Techniques for self-monitoring medication therapy;
14	(7)	Proper storage and appropriate disposal of unwanted or
15		unused medication;
16	(8)	Prescription refill information;
17	(9)	Action to be taken in the event of a missed dose; and
18	(10)	Pharmacist comments relevant to the medication
19		therapy, including any other information peculiar to
20		the specific qualified patient or medication.
21	(d)	Alternative forms of patient information such as
22	written in	nformation leaflets, pictogram labels, or informational
	ap.0.1.0 c=.	

videos, shall be used to supplement medication therapy
 management when appropriate. A pharmacist who uses alternative
 information media pursuant to this subsection shall use the
 pharmacist's professional knowledge and clinical judgment in
 choosing which alternative forms of information to use.

6 (e) A pharmacist shall not provide medication therapy 7 management pursuant to this part for inpatients of a hospital or 8 institution where other licensed health care professionals are 9 authorized to administer medication therapy, except at the 10 request of the hospital or institution and with the consent of 11 the qualified patient.

12 (f) A pharmacist shall not provide medication therapy 13 management to a qualified patient if the patient refuses the 14 service.

15 Patient records. (a) A patient record system that §461-E 16 meets the criteria established by section 328-17.7 shall be 17 maintained by all pharmacies for qualified patients who receive 18 medication therapy management services. The patient record 19 system shall provide for the immediate retrieval of information 20 necessary for a pharmacist to provide medication therapy 21 management and shall be created and stored in a manner that



Page 9

protects against unlawful use or disclosure of protected health 1 2 information. 3 (b) A patient record maintained pursuant to this section 4 shall include: 5 (1)The qualified patient's full name; · 6 (2)The qualified patient's street address and telephone 7 number; The qualified patient's age or date of birth; 8 (3) 9 (4) The qualified patient's sex; 10 (5) A list of all prescription drugs obtained by the 11 qualified patient at a pharmacy within this State in 12 the past two years; 13 The qualified patient's known allergies and prior (6) adverse drug reactions; provided that any adverse drug 14 15 reactions that occur within the course of medication 16 therapy management shall be immediately documented in 17 the patient record; All chronic diseases, disorders, or conditions of the 18 (7)19 patient; The names of any nonprescription drugs, supplements, 20 (8) 21 or other similar substances currently or regularly 22 taken by the qualified patient;

Page 10

S.B. NO. $^{2810}_{S.D.2}$

1	(9) Pharmacist comments relevant to the individual's
2	medication therapy management; and
3	(10) A copy of the collaborative pharmacy practice
4	agreement required under section 461-F.
5	(c) Documentation of activities undertaken by a pharmacist
6	in the course of medication therapy management shall be kept as
7	part of the patient record and shall be readily available to
8	other health care professionals providing care to the qualified
9	patient upon specific authorization by the qualified patient to
10	disclose the information. Documentation recorded or kept
11	pursuant to this section shall be considered protected health
12	information.
13	(d) Protected health information contained in a patient
14	record may be used or disclosed only as allowed under this
15	section, section 461-F, and relevant federal and state law.
16	§461-F Collaborative pharmacy practice agreement. (a) A
17	pharmacist who provides medication therapy management shall have
18	on file at the pharmacist's place of practice a written
19	collaborative pharmacy practice agreement for each qualified
20	patient for whom the pharmacist provides medication therapy
21	management. Parties to the agreement shall be the pharmacist
22	who provides medication therapy management and the qualified
•	SB2810 SD2 LRB 10-1886.doc

1 patient's primary care physician. If a qualified patient does 2 not have a designated primary care physician, any physician or 3 advanced practice nurse practitioner with prescription authority 4 who has ordered a prescription for the qualified patient may be 5 party to the agreement.

6 (b) A collaborative pharmacy practice agreement shall
7 allow a pharmacist, acting within the scope of the pharmacist's
8 license to practice pharmacy, to conduct medication therapy
9 management activities specified in the collaborative pharmacy
10 practice agreement.

11 (c) A collaborative pharmacy practice agreement shall 12 include:

13 (1) Identification of the pharmacist and practitioners who14 are parties to the agreement;

15 (2) The types of medication therapy management actions that the pharmacist may undertake, which may include: 16 A description of the medical conditions 17 (A) 18 experienced by the qualified patient, medications 19 or categories of medications prescribed to the qualified patient, and the activities that the 20 pharmacist may take regarding each condition or 21 medication; 22



Page 11

Page 12

S.B. NO. ²⁸¹⁰ S.D. 2

12

1		(B) A description of the methods, procedures,
2	•	decision criteria, and plan the pharmacist shall
3		follow when conducting allowed activities; and
4		(C) A description of the activities the pharmacist
5		shall follow, including documentation of
6		decisions made, a plan for communication and
7		reporting to the practitioner, and specifications
8		for record keeping;
9	(3)	A method for the practitioner to monitor clinical
10		outcomes and compliance with the agreement and
11		specifications as to when it shall be necessary for
12		the provider to intercede;
13	(4)	A description of the method that a provider shall use
14		to evaluate effectiveness of patient care and ensure
15		positive patient outcomes;
16	(5)	A provision that allows the practitioner to override a
17		medication therapy decision made by the pharmacist if
18		the physician deems it necessary or appropriate;
19	(6)	A provision that requires the pharmacist to report any
20		adverse drug reaction to the provider in writing,
21		immediately upon the pharmacist learning of an adverse
22		reaction;



Page 13

S.B. NO. ²⁸¹⁰ S.D. 2

13

1	(7)	A provision that allows either party to cancel the
2		agreement by written notification;
3	(8)	An effective date;
4	(9)	Signatures of all collaborating pharmacists and
5		practitioners who are party to the agreement; and
6	(10)	Signed authorization by the qualified patient allowing
7		the pharmacists and physicians who are party to the
8		agreement to use and to disclose the qualified
9		patient's protected health information to each other
10		to the extent necessary to effectively participate in
11		medication therapy management and to disclose the
12		qualified patient's protected health information to
13		any other practitioners as authorized by the qualified
14		patient.
15	(d)	Amendments to a collaborative pharmacy practice

16 agreement shall be documented, signed by the pharmacist and 17 physician, and dated.

18 (e) A collaborative pharmacy practice agreement pursuant
19 to this section shall be reviewed, renewed, and revised as
20 necessary at least once every year.

21 (f) A collaborative pharmacy practice agreement may be a
22 standardized document or a checklist-type form developed by the SB2810 SD2 LRB 10-1886.doc

1	physiciar	n, the pharmacist, or the board; provided that the
2	collectiv	ve pharmacy practice agreement meets all of the
3	requireme	ents of this section.
4	§461	-G Rules. The board shall adopt rules pursuant to
5	chapter 9	of to effectuate the purposes of this part."
6	SECT	ION 2. Section 328-17.7, Hawaii Revised Statutes, is
7	amended b	by amending subsections (b) and (c) to read as follows:
8	"(b)	Prescription records [may] shall be electronically
9	maintaine	d using an appropriate prescription information
10	processin	g system; provided that:
11	(1)	There [are] shall be procedures to maintain the
12		records, including but not limited to auxiliary
13		procedures for backing up files, computer downtime,
14		and the protection of patient confidentiality; and
15	(2)	Upon request the prescription records, or a subset
16		thereof, shall be provided to the director or the
17	· .	director's agent, in a form specified by the director,
18		within forty-eight hours.
19	(c)	Prescription records shall be maintained
20	electroni	cally [or-manually] such that the information <u>contained</u>
21	in the re	cords is readily retrievable during the pharmacy's
22	normal op	erating hours."
	SB2810 SD	2 LRB 10-1886.doc

Page 14

S.B. NO. $^{2810}_{S.D.2}$

SECTION 3. Chapter 461, Hawaii Revised Statutes, is
 amended by designating sections 461-1 to 461-22 as part I,
 entitled "General Provisions".
 SECTION 4. Statutory material to be repealed is bracketed
 and stricken. New statutory material is underscored.
 SECTION 5. This Act shall take effect on July 1, 2055.



Page 15

S.B. NO. $^{2810}_{S.D.2}$

Report Title:

Medication Therapy Management; QUEST

Description:

Authorizes pharmacists to provide medication therapy management to qualified QUEST patients. Requires pharmacies to have written collaborative pharmacy practice agreements on file for each qualified patient and have an electronically maintained patient records system for each qualified patient.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

